Trial Profile
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Denovo Biopharma; Eli Lilly and Company
- 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 27 Apr 2012 Planned patient number changed from 950 to 1100 as reported by ClinicalTrials.gov.
- 30 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.